Search | Clinical Trials Finder

Conditions: Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury, Noise-Induced Hearing Loss, Sudden Hearing Loss, Vestibular Dysfunction
Interventions: Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy, Combination Regenerative Therapy; Other · Drug · Biological + 1 more
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2099
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Marqibo® (vincristine sulfate liposomes injection); Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Conditions: Macular Degeneration
Interventions: Celecoxib (Celebrex); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Supportive Care
Interventions: Exercise Training Intervention, Healthy Living Education; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Hyperglycemia
Interventions: intensive glycemic control, conventional glycemic control; Procedure · Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 95 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hepatitis B Virus
Interventions: pegIFN, pegIFNα-2a, PegIFN lambda, Entecavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: Anaheim, California • Garden Grove, California • Sacramento, California + 9 more

Conditions: Aortic Aneurysm, Abdominal
Interventions: Talent Abdominal Stent Graft; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 18
States / cities: Los Angeles, California • Palo Alto, California • Newark, Delaware + 14 more

Conditions: Heart Failure
Interventions: Dietary Approaches to Stop Hypertension Diet; Other
Lead sponsor: University of Georgia; Other
Eligibility: 65 Years to 110 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Clear-Cell Renal Carcinoma
Interventions: rhIL-15, Avelumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatocellular Carcinoma
Interventions: Lenalidomide, Sorafenib; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Nonalcoholic Steatohepatitis
Interventions: pentoxifylline (PTX), placebo; Drug
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Alcohol Use
Interventions: Smartphone brief intervention (SP-BI), Enhanced Usual Care (EUC); Behavioral · Other
Lead sponsor: Keming Gao; Other
Eligibility: Not listed
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Cleveland, Ohio • Toledo, Ohio

Conditions: Physical Inactivity, Overweight or Obesity, Cancer
Interventions: Physical Activity Goals mHealth Intervention, TYPE/CONTEXT enhancement, SAVOR enhancement; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions: Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more

Conditions: Spinal Tumors
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Florida; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acute Graft-versus-host Disease
Interventions: Efmarodocokin Alfa; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Miami, Florida + 5 more

Conditions: PTSD, Military Activity, Post-Traumatic Headache, Posttraumatic Stress Disorder, Posttraumatic Stress Disorder, Delayed Onset, Sleep Disturbance, Nightmare, Irritable Mood, Anger, Combat and Operational Stress Reaction, Combat Stress Disorders, Military Family, Military Operations, Emotional Regulation, Emotion Processing
Interventions: Art Therapy; Behavioral
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • Fort Belvoir, Virginia

Conditions: Erectile Dysfunction, Sexual Dysfunction, Physiological
Interventions: Levitra (Vardenafil, BAY38-9456), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 11
States / cities: Laguna Hills, California • Jeffersonville, Indiana • Des Moines, Iowa + 8 more

Conditions: Infections
Interventions: Ceftaroline fosamil, Ceftriaxone plus vancomycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more

Conditions: Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Lung Carcinoma, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: gammaCore; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Facial Solar Lentigines
Interventions: Revlite Laser System; Device
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: Not listed
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatitis C, Chronic
Interventions: GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 18
States / cities: Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more

Search by objective public record fields.

Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

Laser and Medical Treatment of Diabetic Macular Edema

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms

Effect of DASH on HF Outcomes Heart Failure Status in Older Adults (DASH HF)

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

Pentoxifylline in Patients With Nonalcoholic Steatohepatitis

Project Guard: Reducing Alcohol Misuse/Abuse in the National Guard

eMOTION: Examining Affective Mechanisms in Physical Activity Engagement

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers

Safety and Efficacy of Non-invasive Vagus Nerve Stimulation in the Treatment of Headache in Subarachnoid Hemorrhage

Study for the RevLite Laser System for Facial Solar Lentigines

Metabolic Factors of Outcomes From Gastric Bypass Surgery

Dose Ranging of GSK2336805 in Combination Therapy